StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
BWIV

Blue Water Acquisition Corp. IV

BWIV-UN NYSE Blank Checks EDGAR ↗
$10.11
+0.00 0.00%

Key statistics

from XBRL data in SEC filings
Market cap ⓘ
—
Revenue (TTM) ⓘ
—
Net income (TTM) ⓘ
—
EPS (TTM) ⓘ
—
P/E ratio ⓘ
—
Dividend yield ⓘ
—
Free cash flow ⓘ
—
Cash ⓘ
$0.00
Total assets ⓘ
$132M
Gross margin ⓘ
—
52-week range ⓘ
$9.92 – $10.30

AI briefing

from the latest 10-K, 10-Q and 8-K events

What they do

{ "headline": "Blue Water Acquisition Corp. IV is a blank check company formed to acquire a business, with no operations and a negative shareholder equity.", "what_they_do": "Blue Water Acquisition Corp. IV is a Cayman Islands exempted company incorporated on August 1, 2025, with no material operations. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, or similar business combination with one or more businesses. The company has not selected any business combination target yet, and may pursue a target in any industry, though it expects to focus on biotechnology, healthcare, and technology companies.", "revenue_drivers": [ { "name": "Initial Public Offering proceeds", "detail": "The company holds cash from its IPO and private placement to fund a future business combination; no revenue is generated." } ], "recent_performance": "For the quarter ending March 31, 2026, the company reported total assets of $131.4 million and total liabilities of $4.9 million. Shareholder equity was negative at $-3.7 million. The company had no cash and equivalents on the balance sheet as of that date. Since the last 10-K, the company filed 8-Ks for a director/officer change, entered a material agreement, and had unregistered sales of equity, among other events.", "strategy": "The company intends to use cash from its IPO and private placement, along with potential proceeds from forward purchase or backstop agreements, to fund its initial business combination. It may issue additional shares or incur debt to complete a transaction, which could dilute existing shareholders. Management has not selected a target and is exploring opportunities in biotechnology, healthcare, and technology sectors.", "risks": [ { "title": "No target identified", "detail": "The company has not selected a business combination target and may fail to complete a transaction within the required timeframe." }, { "title": "Potential shareholder dilution", "detail": "Issuing additional shares in a business combination may significantly dilute the equity interest of current investors." }, { "title": "Negative equity", "detail": "The company reports negative shareholder equity of $-3.7 million, indicating liabilities exceed assets." }, { "title": "Debt and default risk", "detail": "If the company incurs significant debt to fund a combination, it could face default and foreclosure if revenues are insufficient." } ], "outlook": "Management expects to focus on a business combination, but has not provided a specific timeline or target. The company will rely on proceeds from its IPO and private placement, and possibly additional financing, to effectuate a transaction. No forward-looking statements have been updated." "key_facts": [ { "label": "Incorporated", "value": "August 1, 2025" }, { "label": "Jurisdiction", "value": "Cayman Islands exempted company" }, { "label": "Total assets (2026-03-31)", "value": "$131.4 million" }, { "label": "Total liabilities (2026-03-31)", "value": "$4.9 million" } ] }